Lung Function

BROVANA: Improved lung function within minutes
Measurement Time
Increase in FEV1 of 10% 2.9 minutes (median)*1
Increase in FEV1 of 15% 6.7 minutes (median)†,2
Increase in FEV1 of 12% and 200 ml 20 minutes (median)†,2
Peak bronchodilator effect 1-3 hours‡,2
  • BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers2
  • BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition
  • BROVANA should not be used with other medications containing LABAs

*Data from 2 identical 12-week, double-blind, placebo-controlled, randomized, multicenter trials (trials A & B) assessing the efficacy and tolerability of nebulized BROVANA 15 mcg twice daily (n=288) vs placebo (n=293) in patients with COPD.

†Data are pooled from clinical trials A and B at Week 0, Day 1.

‡Data are pooled from clinical trials A and B over 12 weeks.


References:

1. Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008;5(1):25-34. 2. BROVANA [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 2011.